(Q44363693)

2 December 2017

title

Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics (English)

1 reference

2 December 2017

Taekyu Lee

1

1 reference

2 December 2017

Albert J Robichaud

2

1 reference

2 December 2017

Kristopher E Boyle

3

1 reference

2 December 2017

Yimin Lu

4

1 reference

2 December 2017

David W Robertson

5

1 reference

2 December 2017

Keith J Miller

6

1 reference

2 December 2017

Larry W Fitzgerald

7

1 reference

2 December 2017

John F McElroy

8

1 reference

2 December 2017

Brian L Largent

9

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Bioorganic & Medicinal Chemistry Letters

2 December 2017

published in

1 reference

2 December 2017

volume

13

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

767-770

1 reference

Developments in the drug treatment of schizophrenia

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Current and novel approaches to the drug treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Atypical antipsychotics--recent findings and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Adverse effects of antipsychotic agents. Do newer agents offer advantages?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

1 reference

7 January 2021

High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

Quipazine-induced head-twitch in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2901028-4

7 January 2021

10.1016/S0960-894X(02)01028-4

Identifiers

DOI

1 reference

2 December 2017

1 reference